WINTON GROUP Ltd Purchases New Holdings in Pfizer Inc. $PFE

Posted by on Sep 12th, 2026

WINTON GROUP Ltd bought a new position in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 135,800 shares of the biopharmaceutical company’s stock, valued at approximately $3,270,000.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Handelsbanken Fonder AB increased its position in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after acquiring an additional 745,213 shares during the period. Leuthold Group LLC purchased a new position in Pfizer during the second quarter valued at approximately $4,887,000. North Dakota State Investment Board bought a new stake in Pfizer during the 4th quarter worth approximately $5,348,000. Finally, Park National Corp OH lifted its stake in Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.1%

PFE stock opened at $27.69 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market capitalization of $157.82 billion, a price-to-earnings ratio of 36.43, a price-to-earnings-growth ratio of 1.86 and a beta of 0.34. The business’s 50 day moving average price is $26.35 and its two-hundred day moving average price is $26.37. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.21.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $0.78 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.39.

Get Our Latest Research Report on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.